<SEC-DOCUMENT>0001178913-22-003865.txt : 20221108
<SEC-HEADER>0001178913-22-003865.hdr.sgml : 20221108
<ACCEPTANCE-DATETIME>20221108084207
ACCESSION NUMBER:		0001178913-22-003865
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221108
FILED AS OF DATE:		20221108
DATE AS OF CHANGE:		20221108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PAINREFORM LTD.
		CENTRAL INDEX KEY:			0001801834
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39481
		FILM NUMBER:		221367401

	BUSINESS ADDRESS:	
		STREET 1:		65 YIGAL ALON ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6744316
		BUSINESS PHONE:		972-3-7177051

	MAIL ADDRESS:	
		STREET 1:		65 YIGAL ALON ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6744316
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2228672.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 22.9.1.5075
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    <div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">Form 6-K</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 195.35pt; margin-left: 194.5pt; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16</div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25; font-weight: bold;">of the Securities Exchange Act of 1934</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; text-indent: -0.05pt; margin-right: 192.55pt; margin-left: 191.7pt; line-height: 1.25;">For the month of November 2022 </div>
      <div style="text-align: center; text-indent: -0.05pt; margin-right: 192.55pt; margin-left: 191.7pt; line-height: 1.25;">Commission File Number: 001-39481</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">PainReform Ltd.</div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; margin-right: 207.5pt; margin-left: 206.65pt; line-height: 1.25;">4 Bruria St. Tel Aviv, 6745442 Israel</div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25;">(Address of principal executive offices)</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
      <div style="margin-left: 5pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25;">Form 20-F <font style="font-family: 'Segoe UI Symbol', 'Segoe UI Symbol', sans-serif;">&#9746;&#160; </font>Form 40-F <font style="font-family: 'Segoe UI Symbol', 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____<br>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">On November 8, 2022, PainReform Ltd. (the &#8220;Company&#8221;) issued a press release entitled &#8220;PainReform Provides PRF-110 Manufacturing Update&#8221;. A copy of the
        press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The press release attached as Exhibit 99.1 to this Form 6-K is incorporated by reference into the Company&#8217;s Registration Statement on Form S-8
        (Registration No. 333-257968 and 333-265902) and the Company&#8217;s Registration Statement on Form F-3 (Registration No. 333-259318).</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">99.1&#160; Press Release dated November 8, 2022</div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25;">Exhibit Index</div>
      <div style="line-height: 1.25">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z619d85370a0143cba25f581b8eabcc1c" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 81pt;">
                <div style="text-align: left; line-height: 1.25;"><u><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exhibit No.</font></u></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; line-height: 1.25;"><u><font style="font-weight: bold; font-family: 'Times New Roman',Times,serif;">Description</font></u></div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdfb7553a216d495c90b49b28d2b5f40c" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 81pt;">
                <div style="text-align: left; line-height: 1.25;"><a href="exhibit_99-1.htm">99.1</a></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; line-height: 1.25;"><a href="exhibit_99-1.htm"><font style="font-family: 'Times New Roman',Times,serif;">Press Release dated
                      November 8, 2022</font></a></div>
              </td>
            </tr>

        </table>
      </div>
      <br>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; margin-right: 117.7pt; margin-left: 116.85pt; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
        authorized.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">
        <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" colspan="2" style="width: 38%;"><font style="font-weight: bold;">PAINREFORM LTD.</font></td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="top" style="width: 35%;">&#160;</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">Date: November 8, 2022&#160;&#160;&#160; <br>
              </td>
              <td valign="top" style="width: 3%; padding-bottom: 2px;">
                <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt">By: </div>
              </td>
              <td valign="top" nowrap="nowrap" align="left" style="width: 35%; border-bottom: #000000 2px solid">/s/ Ilan Hadar&#160;</td>
              <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" align="left" style="width: 35%;">Ilan Hadar <br>
              </td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="top" style="width: 35%;">Chief Executive Officer</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="top" style="width: 35%;">&#160;</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 22.9.1.5075
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div> <br>
    </div>
    <div style="text-align: right;"><u><font style="font-weight: bold;"> Exhibit 99.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25;"><img width="175" height="80" src="image0.jpg"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PainReform Provides Further Update on Manufacturing of PRF-110</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">TEL AVIV, Israel, Nov. 8, 2022 (GLOBE NEWSWIRE) -- &#160;<u>PainReform Ltd.</u>&#160;(Nasdaq: PRFX) ("<font style="font-weight: bold;">PainReform</font>" or the "<font style="font-weight: bold;">Company</font>"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a
            further update related to the manufacturing process of clinical batches for PRF-110.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Ilan Hadar, Chief Executive Officer of Pain Reform,
            stated, &#8220;As <u>previously announced</u>, we implemented additional
            enhancements to our manufacturing process for PRF-110 expected to improve the efficiency and scalability of our manufacturing.&#160; We have since encountered issues in the manufacturing process, which will result in a delay in the
          commencement of our planned Phase 3 trial.&#160; We are moving aggressively on our plans and expect to report further updates as it relates to the expected start of the
            clinical study as soon as practical.&#160; Overall, we remain highly encouraged by the outlook for the business based on the success of our prior Phase 2 proof-of-concept clinical study.&#160; Assuming our Phase 3 trial is successful, we believe
          PRF-110 has the potential to become standard-of-care within the $12 billion post-operative pain treatment market and represents a highly attractive alternative to systemic opioids.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About PainReform</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">PainReform is a clinical-stage specialty pharmaceutical
            company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear
            solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended
            period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit&#160;<u>www.painreform.com</u>.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Notice Regarding Forward-Looking Statements</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-style: italic;">This press release contains forward looking statements about our expectations, beliefs and intentions.
          Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or
          their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of
          management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press
          release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and
          uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the
          following: our history of significant losses, our need to raise additional capital and our ability to obtain additional capital on acceptable terms, or at all; our dependence on the success of our initial product candidate, PRF-110; the outcomes
          of preclinical studies, clinical trials and other research regarding PRF-110 and future product candidates; the impact of the COVID-19 pandemic on our operations; our limited experience managing clinical trials; our ability to retain key
          personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, product manufacturing and development; the impact of competition and new technologies; our ability to comply with regulatory
          requirements relating to the development and marketing of our product candidates; commercial success and market acceptance of our product candidates; our ability to establish sales and marketing capabilities or enter into agreements with third
          parties and our reliance on third party distributors and resellers; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and
          product candidates; the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others; the overall global economic
          environment; our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is volatile; and statements as to the impact of the political and security situation in Israel on our
          business. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 20-F and in other filings that we have made and may make
          with the Securities and Exchange Commission in the future.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">Crescendo Communications, LLC<br>
          Tel: 212-671-1021<br>
          Email:&#160;<u>prfx@crescendo-ir.com</u></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">Ilan Hadar<br>
          Chief Executive Officer<br>
          PainReform Ltd.<br>
          Tel: +972-54-5331725<br>
          Email:&#160;<u>ihadar@painreform.com</u></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageFooter">
        <div style="text-align: center; line-height: 1.25;"><br>
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageFooter">
        <div style="text-align: center; line-height: 1.25;">
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 *\# 2(  A$! Q$!_\0
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MHHH KW__ "#[G_KDW\C7&^"M8T[3?#;+>7<43^<S;"?F(P.W6NROO^0?<_\
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24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
